Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Sarah Skuli

Assistant Professor

University of Cincinnati

United States

Research Interests

Explore related searches

Professors in United States Professors in Cell Biology Cell Biology professors in United States

Articles (11)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (17)

Michael Schnekenburger

Senior Scientist

Luxembourg Institute of Health

LUXEMBOURG

View details

Cholsoon Jang

Associate Professor

University of California, Irvine

UNITED STATES

View details

Robert Baiocchi

UNITED STATES

View details

Nathan Salomonis

Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES

View details

Bradley W. Blaser

Associate Professor with Tenure

Ohio State University

UNITED STATES

View details

Roberta Buono

University of California, Irvine

UNITED STATES

View details

Marc Diederich

Seoul National University

SOUTH KOREA

View details

Keith W. Pratz

UNITED STATES

View details

Sharyn D. Baker

Ohio State University

UNITED STATES

View details

Martin Carroll

University of Pennsylvania

UNITED STATES

View details

Wing Keung Chan

Assistant Professor

Ohio State University

UNITED STATES

View details

Varsha Singh

University of Pennsylvania

UNITED STATES

View details

Deedra Nicolet

Ohio State University

UNITED STATES

View details

Vikram Paralkar

Assistant Professor

University of Pennsylvania

UNITED STATES

View details

Min Zhang

Professor

University of California

UNITED STATES

View details

Linde Miles

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES

View details

Steffen Boettcher

Assistant professor

University Hospital of Zurich

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sarah Skuli

Research Interests

Explore related searches

Articles (11)

Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis

Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia

Upfront menin-inhibitor resistance in multiply pretreated leukemias

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia

Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

A line in shifting sand: Can we define and target TP53 mutated MDS?

Mitohormesis : la clé de voûte de la résistance thérapeutique des cellules cancéreuses

Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.

Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

Collaborators (17)

Michael Schnekenburger

Cholsoon Jang

Robert Baiocchi

Nathan Salomonis

Bradley W. Blaser

Roberta Buono

Marc Diederich

Keith W. Pratz

Sharyn D. Baker

Martin Carroll

Wing Keung Chan

Varsha Singh

Deedra Nicolet

Vikram Paralkar

Min Zhang

Linde Miles

Steffen Boettcher

Make your next move.

Sarah Skuli

Research Interests

Explore related searches

Articles (11)

Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis

Pitavastatin counteracts venetoclax resistance mechanisms including TP53 mutation in acute myeloid leukemia

Upfront menin-inhibitor resistance in multiply pretreated leukemias

TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment.

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia

Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response

NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation

A line in shifting sand: Can we define and target TP53 mutated MDS?

Mitohormesis : la clé de voûte de la résistance thérapeutique des cellules cancéreuses

Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.

Real‐world effectiveness of intensive chemotherapy with 7&amp;3 versus venetoclax and hypomethylating agent in acute myeloid leukemia

Collaborators (17)

Michael Schnekenburger

Cholsoon Jang

Robert Baiocchi

Nathan Salomonis

Bradley W. Blaser

Roberta Buono

Marc Diederich

Keith W. Pratz

Sharyn D. Baker

Martin Carroll

Wing Keung Chan

Varsha Singh

Deedra Nicolet

Vikram Paralkar

Min Zhang

Linde Miles

Steffen Boettcher

Make your next move.

Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia